Our current metabolic peptide research selection includes semaglutide (single GLP-1 agonist), tirzepatide (dual GLP-1/GIP agonist), and retatrutide (triple GLP-1/GIP/glucagon agonist)
J-DAVID InvestigatorsShojiTInabaMFukagawaMAndoREmotoMet al
Being overweight or obese is associated with more than 200 diseases, including cardiovascular disease, type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnoea, certain cancers, and metabolic dysfunction-associated steatotic liver disease (MASLD) [9]
Advantages: no mixing required, concentration is pre-set and verified by pharmacy, less room for reconstitution errors
Efficacy and safety of alogliptin added to pioglitazone therapy in patients with type 2 diabetes